Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy.
Advanced melanoma
Bone metastasis
Denosumab
Nivolumab plus ipilimumab combined therapy
RANKL
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
04
10
2019
accepted:
09
10
2019
entrez:
26
11
2019
pubmed:
26
11
2019
medline:
26
11
2019
Statut:
epublish
Résumé
Nivolumab plus ipilimumab combined therapy is one of the promising drugs that enhance the anti- immune response in patients with advanced melanoma. Therefore, to increase its response rate is of great interest to dermatologists. Recent reports suggested that, since CD8+ T cells after the administration of ICIs increase the RANKL expression to induce an immunosuppressive tumor microenvironment in melanoma, denosumab might enhance the anti-tumor effects of immune checkpoint inhibitors, such as nivolumab and ipilimumab. In this report, we present a case of multiple metastatic melanoma with nivolumab, ipilimumab plus denosumab combined therapy.
Identifiants
pubmed: 31762756
doi: 10.1159/000504019
pii: cro-0012-0829
pmc: PMC6872996
doi:
Types de publication
Case Reports
Langues
eng
Pagination
829-833Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicting interests to declare.
Références
Front Med (Lausanne). 2019 Apr 26;6:86
pubmed: 31080803
J Clin Oncol. 2016 Apr 20;34(12):e104-6
pubmed: 25311221
Cancer Immunol Immunother. 2019 Jul;68(7):1187-1194
pubmed: 31187176
Oncoimmunology. 2018 Feb 14;7(6):e1431088
pubmed: 29872559
J Invest Dermatol. 2011 Apr;131(4):944-55
pubmed: 21270824
J Invest Dermatol. 2015 Oct;135(10):2547-2550
pubmed: 26016897
Expert Rev Anticancer Ther. 2013 Feb;13(2):195-201
pubmed: 23406560
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Ann Oncol. 2017 Jul 1;28(7):1631-1639
pubmed: 28475671
Clin Cancer Res. 2017 Oct 1;23(19):5789-5801
pubmed: 28634284
Br J Dermatol. 2017 Feb;176(2):387-394
pubmed: 27411503
Front Oncol. 2018 Nov 19;8:530
pubmed: 30510916
J Invest Dermatol. 2015 Nov;135(11):2884-2887
pubmed: 26053051